Skip to main content

Table 1 Patients’ characteristics

From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

   n = 40
Age (range)   64.5 (34–73)
Gender Male 23 (57.5%)
Female 17 (42.5%)
Performance status 0 34 (85.0%)
1 6 (15.0%)
Smoking history Yes 23 (57.5%)
Histology Adenocarcinoma 38 (95.0%)
Pleomorphic carcinoma 1 (2.5%)
Non-small cell lung cancer 1 (2.5%)
Stage IIIB 1 (2.5%)
IV 30 (75.0%)
Postoperative recurrence 9 (22.5%)
EGFR mutation Positive 23 (57.5%)
Negative 16 (40.0%)
Unknown 1 (2.5%)
Previous adjuvant chemotherapy Yes 6 (15.0%)
Previous EGFR-TKI therapy Yes 8 (20.0%)
  1. EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor